Compare · PULM vs SVRA

PULM vs SVRA

Side-by-side comparison of Pulmatrix Inc. (PULM) and Savara Inc. (SVRA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both PULM and SVRA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • SVRA is the larger of the two at $987.3M, about 197.3x PULM ($5.0M).
  • PULM has been more active in the news (8 items in the past 4 weeks vs 4 for SVRA).
  • SVRA has more recent analyst coverage (12 ratings vs 0 for PULM).
MetricPULMSVRA
Company
Pulmatrix Inc.
Savara Inc.
Price
-
-
Market cap
$5.0M
$987.3M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2014
News (4w)
8
4
Recent ratings
0
12
PULM

Pulmatrix Inc.

Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal infections and allergic/hypersensitivity reactions to fungus in patients with severe lung diseases comprising asthma, cystic fibrosis, and allergic bronchopulmonary aspergillosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with lung cancer and chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

SVRA

Savara Inc.

Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Latest PULM

Latest SVRA